Forzinity Elamipretide: The randomized trial did not show a benefit. The disease has no alternatives.
We recently completed a MARA Rating for a treatment for Barth syndrome — a rare, life-threatening disease that affects young men and has no established disease-modifying therapy. The randomized trial